Pharmacological modulation of cardiac myofibroblast-specific cGKI should provide new opportunities to optimize existing treatments aimed at improving or even reversing hypertensive heart disease, one of the major causes of heart failure. The gene discussed is PRKG1; the disease is heart failure.